In summary, we demonstrated that paroxetine and a related GRK2 inhibitor not only have an attractive clinical prospect in targeting allergic reactions, but also may serve to enhance host defense via MRGPRX2/MRGPRB2 activation. This evidence concerns the gene MRGPRX2 and allergic disease.